Displaying 47 (all) recruiting clinical trials.
-
A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
The purpose of this study is to test the safety of a study drug called TJ033721. The study will test different dose levels to find ... -
A Phase 1 Open-Label Multi-Center Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination with Docetaxel in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
The purpose of this first-in-human (FIH) study is to investigate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), maximum tolerated dose (MTD), recommended Phase 2 dose ... -
A phase 1/1b/2 study evaluating the safety tolerability pharmacokinetics pharmacodynamics and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD ... -
CP-CGMH: Care Partner-Assisted Diabetes Self-Management Through Linking Continuous Glucose Monitoring with Mobile Health: Improving Outcomes for Older Adults with Mild Cognitive Impairment
The purpose of this study is to examine the acceptability of continuous glucose monitoring (CGM) and identify the key domains of a future care partner-assisted ... -
Phase I open-label trial evaluating BI 1810631 as monotherapy in the treatment of patients with advanced or metastatic solid tumors with HER2 aberrations (BEAMION-Lung 1)
This is a Phase I, open-label, multicentre trial of BI 1810631 administered orally as a single agent. The trial has two parts; Phase Ia, which ... -
A Phase I Study of ExoFlo an ex vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product for the Treatment of Medically Refractory Ulcerative Colitis
Patients with Ulcerative Colitis are often managed with corticosteroids, immunomodulators and monoclonal antibodies, all fraught with potential side effects. The advent of the biologic era ... -
A Phase 1 Multicenter Open-Label Study Of CC-97540 (BMS-986353) CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells in Participants with Severe Refractory Autoimmune Diseases: Systemic Lupus Erythematosus Idiopathic Inflammatory Myopathy or Systemic Sclerosis
SLE disease activity results in accumulation of tissue and organ damage (eg, nephritis, multisystem organ failure, and central nervous disease) that contributes to morbidity and ... -
A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone or in Combination in Participants with Solid Tumors
This is a 2-part, open-label, Phase 1, multicenter dose-escalation, FIH study of mRNA-4157 monotherapy in subjects with resected solid tumors (Part A) who are in ... -
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810) ADMINISTERED INTRALESIONALLY FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC)
The primary objective is to characterize the safety and tolerability of cemiplimab (also known as REGEN2810) injected intralesionally in patients with recurrent cutaneous squamous cell ... -
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies
This is a Phase 1, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and clinical activity of AB680 (CD73 inhibitor) in ...